According to Shenlian Biotech's announcement, it achieved operating income of 112 million yuan in the first half of 2026, a year-on-year decrease of 8.05%; net loss attributable to shareholders of listed companies of 19.1464 million yuan, net loss of 12.8697 million yuan for the same period last year; and net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 19.15,800 yuan. R&D investment accounted for 19.91% of revenue, a year-on-year decrease of 2.41 percentage points. The company achieved the holding of WorldSource step by step and strategically entered the field of innovative pharmaceuticals.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.